Product Description
IMP1734 is a novel and highly PARP1 selective inhibitor with high potency of inhibiting PARP1 and low activity of inhibiting PARP2. Preclinical in vivo models had demonstrated high anti-tumor activities and a wide therapeutic window. The improved therapeutic index of IMP1734 over currently marketed non-selective PARP1/2 inhibitors supports its development as monotherapy and in combination with other agents. (Sourced from: http://www.impacttherapeutics.com/en/new/168.html)
Mechanisms of Action: PARP Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eikon Therapeutics
Company Location: Western America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Denmark, France, Spain, United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Breast Cancer|Oncology Solid Tumor Unspecified|Ovarian Cancer|Prostate Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2023-509230-19-00 |
EIK1003-001 | P2 |
Recruiting |
Oncology Solid Tumor Unspecified |
2026-02-27 |
2025-05-02 |
Treatments |
|
NCT06253130 |
EIK1003-001 (IMP1734-101) | P2 |
Recruiting |
Prostate Cancer|Ovarian Cancer|Breast Cancer |
2026-02-01 |
12% |
2024-02-14 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/15/2025 |
News Article |
Eikon Therapeutics to Present New Phase 2 Data on EIK1001 in First-Line Non-Small Cell Lung Cancer at ESMO 2025 |
|
05/29/2025 |
News Article |
Eikon Therapeutics to Share Clinical Data and Program Updates at the 2025 ASCO Annual Meeting |
|
02/26/2025 |
News Article |
Eikon Therapeutics Secures $350.7 Million Series D to Advance Clinical-Stage Programs and Future Pipeline |
|
05/28/2024 |
News Article |
Eikon Therapeutics Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting |